Progression of HIV infection and mortality by hepatitis C infection in patients with haemophilia over 20 years

Haemophilia

Volumn 9, Issue 5, 2003, Pages 605-612

  Quintana, M ^a   del Amo, Julia ^b   Barrasa, A ^c   Perez Hoyos S ^d   Ferreros, I ^d   Hernandez F ^a   Villar, A ^a   Jimenez V ^a   Bolumar F ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c CARLOS III INSTITUTE OF HEALTH   (Spain)

^d Generalitat Valenciana   (Spain)

Author keywords

Haemophilics; HIV progression; Natural history; Sero converters

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHILD; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEMOPHILIA; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; REGRESSION ANALYSIS; SEROCONVERSION; SPAIN; STATISTICAL SIGNIFICANCE; UNIVERSITY HOSPITAL;

EID: 0141990546     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2003.00804.x     Document Type: Article

References (29)

1. Ragni MV, Tegtmeier GE, Levy JA et al. AIDS retrovirus antibodies in hemophiliacs treated with factor VIII or factor IX concentrates, cryoprecipitate, or fresh frozen plasma: prevalence, seroconversion rate, and clinical correlations. Blood 1986; 67: 592-5.
2. Eyster ME, Gail MH, Ballard JO, Al-Mondhiry H, Goedert JJ. Natural history of human immunodeficiency virus infections in haemophilics: effects of T-cell subsets, platelet counts, and age. Ann Intern Med 1987; 107: 1-6.
3. Darby SC, Ewart DW, Giangrande PLF, Spooner JD, Rizza CR for the UK Haemophilia Centre Directors' Organisation. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. Lancet 1996; 347: 1573-9.
4. Sabin CA, Yee TT, Devereux H et al. Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy. AIDS 2000; 14: 1001-7.
5. Darby SC, Ewart DW, Giangrande PL et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997; 350: 1425-31.
6. Eyster ME, Sherman KE, Goedert JJ, Katsoulidou A, Hatzakis A. Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with haemophilia: the Multicenter Haemophilia Cohort Study. J Infect Dis 1999; 179: 1062-9.
7. Lee C, Dusheiko G. The natural history and antiviral treatment of hepatitis C in haemophilia. Haemophilia 2002; 8: 322-9.
8. Prins M, Sabin CA, Lee CA, Devereux H, Coutinho RA. Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men. AIDS 2000; 14: 1829-37.
9. Goedert JJ, Eyster ME, Lederman MM et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002; 100: 1584-9.
10. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001; 183: 1112-5.
11. Sabin CA, Griffioen A, Yee TT et al. Markers of HIV-1 disease progression in individuals with haemophilia coinfected with hepatitis C virus: a longitudinal study. Lancet 2002; 360: 1546-51.
12. Ministry of Health. Circular de 30 de septiembre de 1985, de la Dirección General de Farmacia y Productos Sanitarios, por los que se dan normas aclaratorias para el mejor cumplimiento de la Resolución de 6 de septiembre de 1985. Boletín Oficial del estado no. 235 de Martes 1 de Octubre de 1985.
13. AIDS Surveillance in Spain. Registro nacional de casos de Sida. Balance de la epidemia a 30 de junio de 2003. Actualización a 30 de junio de 2002, http://www.msc/sida.es
14. Delladetsima J, Katsarou O, Touloumi G, Vgenopoulou S, Hatzakis A, Karafoulidou A. Significance of immune status, genotype and viral load in the severity of chronic hepatitis C in HIV infected haemophilia patients. Haemophilia 2002; 8: 668-73.
15. Detels R, Muñoz A, McFarlane G et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280: 1497-503.
16. CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV infection. Lancet 2000; 355: 1158-9.
17. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Eng J Med 2001; 338: 853-60.
18. Pérez-Hoyos S, Del Amo J, Muga R et al. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS 2003; 17(3): 353-9.
19. Ministry of Relations with Parliament. Real Decreto Ley 9/1993 de 28 de mayo, por el que se conceden ayudas a los afectados por el Virus de Inmunodeficiencia Humana (VIH) como consecuencia de actuaciones realizadas en el sistema sanitario público. Boletín Oficial del estado no. 130 de Martes 1 de junio de 1993.
20. Porter K, Johnson AM, Phillips AN, Darbyshire JH. The practical significance of potential biases in estimates of the AIDS incubation periods distribution in the UK Register of HIV Seroconverters. AIDS 1999; 13: 1943-51.
21. Barrasa A, Castilla J, Pereira J, Herrera D, Martinez-Navarro F. Estimating the completeness of AIDS reporting in Spain. Gac Sanit 2001; 15: 482-9.
22. Ajdacic-Gross V, Zellweger U, Wang J, Fleerackers Y, Somani B. How complete is AIDS surveillance in Europe? An eagle eye comparison with mortality data. J Epidemiol Community Health 2001; 55: 52-6.
23. Clayton D, Hills M. Statistical Models in Epidemiology. Oxford: Oxford university Press, 1993.
24. Alcabes P, Muñoz A, Vlahov D, Friedland GH. Incubation period of human immunodeficiency virus. Epidemiol Rev 1993; 15: 303-18.
25. Del Amo J, Del Romero J, Barrasa A, Pérez-Hoyos S, Rodríguez C, Díez M and the Grupo de Seroconvertores de la Comunidad de Madrid. Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999. STI 2002; 78: 255-60.
26. GEMES (Grupo Español Multicéntrico para el Estudio de Seroconvertores). El periodo de incubación del SIDA en España antes de la terapia HAART. Med Clin 2000; 115: 681-6.
27. CASCADE Collaboration. Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol 2002; 31: 951-8.
28. Sabin CA, Telfer P, Phillips AN, Bhagani S, Lee CA. The association between hepatitis virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis 1997; 175: 164-8.
29. Rosenberg PS, Goedert JJ. Estimating the cumulative incidence of HIV infection among persons with haemophilia in the United States of America. Stat Med 1998; 17: 155-68.